{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:22:01Z","timestamp":1789593721481,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600114"],"award-info":[{"award-number":["81600114"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400155"],"award-info":[{"award-number":["81400155"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20140374"],"award-info":[{"award-number":["BK20140374"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04236-4","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:16:19Z","timestamp":1762953379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma"],"prefix":"10.1007","volume":"74","author":[{"given":"Lingzi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqing","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changju","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"2","key":"4236_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","volume":"80","author":"K Jahnke","year":"2006","unstructured":"Jahnke K, Thiel E, Martus P et al (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80(2):159\u2013165. https:\/\/doi.org\/10.1007\/s11060-006-9165-6","journal-title":"J Neurooncol"},{"issue":"5","key":"4236_CR2","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E et al (2016) Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3(5):e217-227. https:\/\/doi.org\/10.1016\/S2352-3026(16)00036-3","journal-title":"Lancet Haematol"},{"issue":"7","key":"4236_CR3","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJ Ferreri","year":"2022","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E et al (2022) Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 36(7):1870\u20131878. https:\/\/doi.org\/10.1038\/s41375-022-01582-5","journal-title":"Leukemia"},{"issue":"26","key":"4236_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"1","key":"4236_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"10254","key":"4236_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"issue":"15","key":"4236_CR7","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","volume":"139","author":"MJ Frigault","year":"2022","unstructured":"Frigault MJ, Dietrich J, Gallagher K et al (2022) Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood 139(15):2306\u20132315. https:\/\/doi.org\/10.1182\/blood.2021014738","journal-title":"Blood"},{"issue":"12","key":"4236_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000984","volume":"7","author":"E Shumilov","year":"2023","unstructured":"Shumilov E, Boyadzhiev H, Mazzeo P et al (2023) CAR-T cell therapy shows similar efficacy and toxicity in patients with DLBCL regardless of CNS involvement. HemaSphere 7(12):e984. https:\/\/doi.org\/10.1097\/HS9.0000000000000984","journal-title":"HemaSphere"},{"issue":"12","key":"4236_CR9","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1093\/neuonc\/noad118","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Arrillaga-Romany IC, Eichler A et al (2023) Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol 25(12):2239\u20132249. https:\/\/doi.org\/10.1093\/neuonc\/noad118","journal-title":"Neuro Oncol"},{"issue":"1","key":"4236_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Feng L, Shah NN et al (2023) Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol 16(1):111. https:\/\/doi.org\/10.1186\/s13045-023-01508-3","journal-title":"J Hematol Oncol"},{"issue":"3","key":"4236_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/bjh.19569","volume":"205","author":"N Epperla","year":"2024","unstructured":"Epperla N, Hashmi H, Ahn KW et al (2024) Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: a CIBMTR analysis. Br J Haematol 205(3):1202\u20131207. https:\/\/doi.org\/10.1111\/bjh.19569","journal-title":"Br J Haematol"},{"issue":"4","key":"4236_CR12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41409-020-01099-4","volume":"56","author":"S Ghafouri","year":"2021","unstructured":"Ghafouri S, Timmerman J, Larson S et al (2021) Axicabtagene ciloleucel CAR T-cell therapy for relapsed\/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies? Bone Marrow Transplant 56(4):974\u2013977. https:\/\/doi.org\/10.1038\/s41409-020-01099-4","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4236_CR13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3324\/haematol.2024.285613","volume":"110","author":"S Mercadal","year":"2025","unstructured":"Mercadal S, Ahn KW, Allbee-Johnson M et al (2025) Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy. Haematologica 110(1):218\u2013221. https:\/\/doi.org\/10.3324\/haematol.2024.285613","journal-title":"Haematologica"},{"issue":"18","key":"4236_CR14","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1182\/bloodadvances.2023010336","volume":"7","author":"F Ayuk","year":"2023","unstructured":"Ayuk F, Gagelmann N, von Tresckow B et al (2023) Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA\/DRST study. Blood Adv 7(18):5316\u20135319. https:\/\/doi.org\/10.1182\/bloodadvances.2023010336","journal-title":"Blood Adv"},{"key":"4236_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fimmu.2020.00538","volume":"11","author":"ND Ebelt","year":"2020","unstructured":"Ebelt ND, Zuniga E, Johnson BL et al (2020) 5-azacytidine potentiates anti-tumor immunity in a model of pancreatic ductal adenocarcinoma. Front Immunol 11:538. https:\/\/doi.org\/10.3389\/fimmu.2020.00538","journal-title":"Front Immunol"},{"issue":"1","key":"4236_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/CJI.0000000000000284","volume":"43","author":"C Qu","year":"2020","unstructured":"Qu C, Ping N, Kang L et al (2020) Radiation priming chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden. J Immunother 43(1):32\u201337. https:\/\/doi.org\/10.1097\/CJI.0000000000000284","journal-title":"J Immunother"},{"issue":"7","key":"4236_CR17","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41409-021-01230-z","volume":"56","author":"C Qu","year":"2021","unstructured":"Qu C, Song Y, Yin J et al (2021) Decitabine may improve CAR-T efficacy in refractory\/relapsed acute leukemia patients carrying TP53 alterations. Bone Marrow Transplant 56(7):1710\u20131713. https:\/\/doi.org\/10.1038\/s41409-021-01230-z","journal-title":"Bone Marrow Transplant"},{"issue":"27","key":"4236_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"22","key":"4236_CR19","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23(22):5034\u20135043. https:\/\/doi.org\/10.1200\/JCO.2005.13.524","journal-title":"J Clin Oncol"},{"issue":"4","key":"4236_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"4236_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook MR, Dorris CS, Makambi KH et al (2023) Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv 7(1):32\u201339. https:\/\/doi.org\/10.1182\/bloodadvances.2022008525","journal-title":"Blood Adv"},{"issue":"5","key":"4236_CR22","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/leu.2008.18","volume":"22","author":"BL Pike","year":"2008","unstructured":"Pike BL, Greiner TC, Wang X et al (2008) DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 22(5):1035\u20131043. https:\/\/doi.org\/10.1038\/leu.2008.18","journal-title":"Leukemia"},{"issue":"10","key":"4236_CR23","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/ijc.22124","volume":"119","author":"LC Chu","year":"2006","unstructured":"Chu LC, Eberhart CG, Grossman SA et al (2006) Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer 119(10):2487\u20132491. https:\/\/doi.org\/10.1002\/ijc.22124","journal-title":"Int J Cancer"},{"issue":"2","key":"4236_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00401-016-1664-8","volume":"133","author":"T Nakamura","year":"2017","unstructured":"Nakamura T, Yamashita S, Fukumura K et al (2017) Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. Acta Neuropathol 133(2):321\u2013324. https:\/\/doi.org\/10.1007\/s00401-016-1664-8","journal-title":"Acta Neuropathol"},{"key":"4236_CR25","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.2147\/OTT.S198567","volume":"12","author":"S Li","year":"2019","unstructured":"Li S, Xue L, Wang M et al (2019) Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma. Onco Targets Ther 12:5627\u20135638. https:\/\/doi.org\/10.2147\/OTT.S198567","journal-title":"Onco Targets Ther"},{"key":"4236_CR26","doi-asserted-by":"publisher","first-page":"969660","DOI":"10.3389\/fimmu.2022.969660","volume":"13","author":"C Qu","year":"2022","unstructured":"Qu C, Zou R, Wang P et al (2022) Decitabine-primed tandem CD19\/CD22 CAR-T therapy in relapsed\/refractory diffuse large B-cell lymphoma patients. Front Immunol 13:969660. https:\/\/doi.org\/10.3389\/fimmu.2022.969660","journal-title":"Front Immunol"},{"issue":"1","key":"4236_CR27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang Y, Tong C, Dai H et al (2021) Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat Commun 12(1):409. https:\/\/doi.org\/10.1038\/s41467-020-20696-x","journal-title":"Nat Commun"},{"issue":"8","key":"4236_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","volume":"27","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Patel S, Muffly L et al (2021) CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 27(8):1419\u20131431. https:\/\/doi.org\/10.1038\/s41591-021-01436-0","journal-title":"Nat Med"},{"issue":"4","key":"4236_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) Car-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"issue":"10450","key":"4236_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","volume":"404","author":"MJ Frank","year":"2024","unstructured":"Frank MJ, Baird JH, Kramer AM et al (2024) CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study. Lancet 404(10450):353\u2013363. https:\/\/doi.org\/10.1016\/S0140-6736(24)00746-3","journal-title":"Lancet"},{"issue":"17","key":"4236_CR31","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1182\/blood.2020009432","volume":"137","author":"JH Baird","year":"2021","unstructured":"Baird JH, Frank MJ, Craig J et al (2021) CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood 137(17):2321\u20132325. https:\/\/doi.org\/10.1182\/blood.2020009432","journal-title":"Blood"},{"issue":"20","key":"4236_CR32","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1182\/blood.2022018598","volume":"141","author":"C Roddie","year":"2023","unstructured":"Roddie C, Lekakis LJ, Marzolini MAV et al (2023) Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma. Blood 141(20):2470\u20132482. https:\/\/doi.org\/10.1182\/blood.2022018598","journal-title":"Blood"},{"issue":"7","key":"4236_CR33","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood.2021012634","volume":"139","author":"EA Chong","year":"2022","unstructured":"Chong EA, Alanio C, Svoboda J et al (2022) Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood 139(7):1026\u20131038. https:\/\/doi.org\/10.1182\/blood.2021012634","journal-title":"Blood"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04236-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:20Z","timestamp":1764600320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04236-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4236"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04236-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"1 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was obtained from the patient for the publication of any potentially identifiable data included in this article. This study was approved by Medical Ethics Committee of the First Affiliated Hospital of Soochow University (2025004).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"372"}}